- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04429464
AcQBlate Force Confirmatory Study for Atrial Arrhythmias
October 12, 2021 updated by: Acutus Medical
AcQBlate Force Confirmatory Study for Atrial Arrhythmias (AcQBlate Force-PRA)
AcQBlate Force Confirmatory Study for Atrial Arrhythmias (AcQBlate Force-PRA)
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Detailed Description
Acutus Medical's AcQBlate Force Ablation Catheter when used in combination with the Qubic Force Sensing Module (AcQBlate Force System), is indicated for cardiac electrophysiological mapping, delivery of diagnostic pacing stimuli, and radiofrequency ablation of sustained or recurrent atrial arrhythmias.
Study Type
Interventional
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Prague, Czechia, 150 30
- Na Homolce Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female between the ages of 18 to 80 years at time of consent.
- Clinically indicated and scheduled for a de novo or repeat catheter ablation of PAF or PerAF
- Willing and able to provide written informed consent to to participate in the study and agree to comply with all follow-up visits and evaluations for the duration of the study.
Exclusion Criteria:
- In the opinion of the investigator, any contraindication to the planned atrial ablation, including anticoagulation contraindications or sepsis
- Continuous AF > 12-months (long-standing persistent AF)
- Atrial arrhythmias secondary to electrolyte imbalance, thyroid disease, or any other reversible or non-cardiac cause.
- An implanted pacemaker or Implantable Cardiac Defibrillator (ICD).
- Structural heart disease or cardiac history as described below:
- Left ventricular ejection fraction (LVEF) < 35% based on transthoracic echocardiogram (TTE) within the previous 180-days.
- Left atrial size > 55 mm based on TTE within the previous 180-days.
- Evidence of heart failure (NYHA Class III or IV).
- Previous cardiac surgery, ventriculotomy, or atriotomy (excluding atriotomy for coronary artery bypass).
- Previous cardiac valvular surgical or percutaneous procedure, or prosthetic valve.
- Coronary artery bypass graft (CABG) or coronary angioplasty (PTCA) procedure within the last 90-days.
- Unstable angina or ongoing myocardial ischemia.
- Severe uncontrolled systemic hypertension (systolic pressure > 240 mm Hg, diastolic pressure > 140 mm Hg recorded within the last 30-days.
- Moderate or severe tricuspid stenosis or regurgitation.
- Moderate or severe mitral stenosis or regurgitation.
- Interatrial baffle, closure device, patch, or patent foramen ovale (PFO) occluder.
- Presence of a left atrial appendage occlusion device.
- Previous PV stenting or evidence of PV stenosis
- Body Mass Index (BMI) >40 kg/m2
- History of blood clotting or bleeding disease.
- Any prior history of documented cerebral infarct or systemic embolism (excluding post- operative deep vein thrombosis (DVT)).
- Pregnant or lactating (current or anticipated during study follow up).
- Current enrollment in any other study protocol where testing or results from the study may interfere with the procedure or outcome measurements for this study.
- Any other condition that, in the judgment of the investigator, makes the patient a poor candidate for this procedure, the study or compliance with the protocol (includes vulnerable patient population, mental illness, addictive disease, terminal illness with a life expectancy of less than two years, extensive travel away from the research center)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Non-randomized
All subjects will be treated using the Acutus Medical's AcQBlate Force Sensing Ablation Catheter in combination with the Qubic Force Sensing Module (AcQBlate Force Sensing System) to treat their arrhythmia.
|
Confirmation that the AcQBlate Force System is safe and effective for the treatment of atrial arrhythmias
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Subjects that demonstrate electrical isolation of the intended ablation
Time Frame: At the end of their ablation procedure
|
The Primary Endpoint for Performance is an analysis of the proportion of subjects that demonstrate electrical isolation (block) of the intended ablation targets.
|
At the end of their ablation procedure
|
Proportion of subjects who are free from device/procedure related Major Adverse Events
Time Frame: Through 30-days post procedure
|
The Primary Endpoint for Safety is an analysis of the proportion of subjects who are free from device/procedure related Major Adverse Events (MAEs) that occur following the ablation procedure through 30-days.
|
Through 30-days post procedure
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Subjects with freedom from an atrial arrhythmia
Time Frame: 30-days post index procedure
|
The Secondary Endpoint for Performance is documentation of subjects with freedom from an atrial arrhythmia at 30-days post index procedure.
|
30-days post index procedure
|
Analysis of all identified SAEs, SADEs, and UADEs.
Time Frame: Through 30-days post procedure
|
The Secondary Endpoint for Safety is a recording and analysis of all identified serious adverse events (SAEs), serious adverse device effects (SADEs), and unanticipated adverse device effects (UADEs) through 30-days post-procedure.
|
Through 30-days post procedure
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
October 1, 2020
Primary Completion (Anticipated)
November 15, 2020
Study Completion (Anticipated)
November 15, 2020
Study Registration Dates
First Submitted
June 10, 2020
First Submitted That Met QC Criteria
June 11, 2020
First Posted (Actual)
June 12, 2020
Study Record Updates
Last Update Posted (Actual)
October 20, 2021
Last Update Submitted That Met QC Criteria
October 12, 2021
Last Verified
October 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CLP-14
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atrial Arrhythmias
-
TriVirum, Inc.CompletedAtrial Fibrillation | Arrhythmias, Cardiac | Paroxysmal Atrial Fibrillation | Afib | Irregular Heart Beat | Arrhythmia Atrial | Arrhythmias ParoxysmalUnited States
-
University Hospital, BordeauxCompletedVentricular Arrhythmias | Persistent Atrial FibrillationFrance
-
Abbott Medical DevicesCompletedCardiac Arrhythmia | Paroxysmal Atrial Fibrillation | Persistent Atrial FibrillationSpain, United Kingdom, Germany, Italy, Austria, Czechia, France, Netherlands, Portugal
-
CathVision ApSMedicept IncActive, not recruitingCardiac Arrhythmia | Persistent Atrial FibrillationUnited States
-
Angelo BivianoCompleted
-
Barts & The London NHS TrustMedtronicCompletedCardiac Arrhythmia | Persistent Atrial FibrillationUnited Kingdom
-
University of Sao Paulo General HospitalMedtronicCompletedCardiac Arrythmias | Atrial Fibrillation ParoxysmalBrazil
-
Barts & The London NHS TrustNot yet recruitingInvestigation of Cardioversion Versus Therapeutic Ablation for Persistent AF (ORBICA-AF) (ORBICA-AF)Cardiac Arrhythmia | Persistent Atrial Fibrillation | Catheter Ablation
-
Adagio MedicalRecruitingAtrial Fibrillation | Atrial Flutter | Paroxysmal Atrial Fibrillation | Persistent Atrial FibrillationNetherlands, Germany, Belgium
-
St. George's Hospital, LondonRecruitingAtrial Fibrillation | Atrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Atrial ArrhythmiaUnited Kingdom
Clinical Trials on AcQBlate Force Sensing Ablation Catheter
-
Acutus MedicalCompletedTypical Atrial FlutterBelgium, United States, United Kingdom
-
Acutus MedicalNot yet recruitingParoxysmal Atrial Fibrillation | Persistent Atrial Fibrillation
-
Acutus MedicalWithdrawnParoxysmal Atrial Fibrillation | Persistent Atrial Fibrillation
-
Acutus MedicalCompletedTypical Atrial FlutterBelgium, United Kingdom
-
Erasmus Medical CenterUnknownTachycardia, Supraventricular | Tachycardia; Paroxysmal, SupraventricularNetherlands
-
Ningbo No. 1 HospitalCompletedParoxysmal Supraventricular TachycardiaChina
-
Shanghai MicroPort EP MedTech Co., Ltd.Active, not recruitingParoxysmal Supraventricular TachycardiaChina
-
Queen Mary University of LondonCompletedAtrial Fibrillation | Atrial Fibrillation Ablation | Pulmonary Vein IsolationUnited Kingdom
-
L.V.A. BoersmaCompleted
-
Abbott Medical DevicesCompletedPersistent Atrial FibrillationUnited States, Australia